Company Encyclopedia
View More
name
Epigenomics AG
ECX.DE
News
View More

Epigenomics AG Releases Presentation for Upcoming Annual General Meeting on August 27, 2025

Epigenomics AG has released a presentation for its upcoming annual general meeting on August 27, 2025. The document outlines the agenda, including key proposals such as the discharge of the supervisory and executive boards for fiscal year 2024, auditor appointment for fiscal year 2025, approval of the executive board’s remuneration system, and relocation of the company’s headquarters. Detailed voting results for each proposal are also included. The full presentation is accessible via a provided link.

Reuters·
DE
ECX
0.00%
Reuters·
DE
ECX
0.00%

Epigenomics AG Announces Date for 2025 Annual General Meeting

Epigenomics AG will hold its Annual General Meeting on August 27, 2025, in Frankfurt, Germany. A key agenda item includes a resolution on relocating the company's registered office. This announcement was generated by Public Technologies and is for informational purposes only.

Reuters·
DE
ECX
0.00%
Reuters·
DE
ECX
0.00%

Epigenomics AG to Release Financial Results for the First Half of 2025

Epigenomics AG will release its interim financial report for the first half of 2025 on July 22, 2025. The report will be available online. This announcement is for informational purposes only and should not be considered financial, investment, or legal advice.

Reuters·
DE
ECX
0.00%
Reuters·
DE
ECX
0.00%

Epigenomics AG Reports H1 2025 Loss of 204 TEUR, Sales Increase to 4 TEUR from 0 TEUR

Epigenomics AG reported a reduced net loss of 204 TEUR for H1 2025, down from 796 TEUR in H1 2024, with revenues increasing to 4 TEUR from 0 TEUR. Liquid funds decreased to 764 TEUR from 927 TEUR at the end of 2024. The financial result improved to +22 TEUR, attributed to interest income. Negative equity slightly increased to 11.065 million EUR. The company maintains its annual forecast for a net loss between 0.1 million EUR and 0.5 million EUR.

Reuters·
DE
ECX
0.00%
Reuters·
DE
ECX
0.00%

Decrease in Total Voting Rights Held by Wilhelm K. T. Zours in Epigenomics AG

Wilhelm K. T. Zours has reduced his total voting rights in Epigenomics AG from 58.32% to 56.75%, a decrease of 1.57 percentage points. The voting rights associated with shares remain unchanged at 29.06%.

Reuters·
DE
ECX
0.00%
Reuters·
DE
ECX
0.00%